ProQR Therapeutics/$PRQR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ProQR Therapeutics
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
Ticker
$PRQR
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
166
ISIN
NL0010872495
Website
PRQR Metrics
BasicAdvanced
$228M
-
-$0.39
0.35
-
Price and volume
Market cap
$228M
Beta
0.35
52-week high
$4.04
52-week low
$1.07
Average daily volume
330K
Financial strength
Current ratio
4.095
Quick ratio
4.009
Long term debt to equity
13.604
Total debt to equity
21.35
Interest coverage (TTM)
-30.84%
Profitability
EBITDA (TTM)
-37.791
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-153.80%
Operating margin (TTM)
-169.23%
Effective tax rate (TTM)
0.66%
Revenue per employee (TTM)
$140,260
Management effectiveness
Return on assets (TTM)
-15.07%
Return on equity (TTM)
-53.07%
Valuation
Price to revenue (TTM)
8.664
Price to book
2.88
Price to tangible book (TTM)
2.88
Price to free cash flow (TTM)
-4.479
Free cash flow yield (TTM)
-22.33%
Free cash flow per share (TTM)
-48.23%
Growth
Revenue change (TTM)
85.91%
Earnings per share change (TTM)
1.72%
3-year revenue growth (CAGR)
77.88%
10-year revenue growth (CAGR)
40.67%
3-year earnings per share growth (CAGR)
-28.27%
10-year earnings per share growth (CAGR)
-6.40%
What the Analysts think about PRQR
Analyst ratings (Buy, Hold, Sell) for ProQR Therapeutics stock.
PRQR Financial Performance
Revenues and expenses
PRQR Earnings Performance
Company profitability
PRQR News
AllArticlesVideos
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
GlobeNewsWire·1 day ago
ProQR Announces First Quarter 2025 Operating and Financial Results
GlobeNewsWire·2 months ago
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ProQR Therapeutics stock?
ProQR Therapeutics (PRQR) has a market cap of $228M as of June 27, 2025.
What is the P/E ratio for ProQR Therapeutics stock?
The price to earnings (P/E) ratio for ProQR Therapeutics (PRQR) stock is 0 as of June 27, 2025.
Does ProQR Therapeutics stock pay dividends?
No, ProQR Therapeutics (PRQR) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next ProQR Therapeutics dividend payment date?
ProQR Therapeutics (PRQR) stock does not pay dividends to its shareholders.
What is the beta indicator for ProQR Therapeutics?
ProQR Therapeutics (PRQR) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.